Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.

Fehlings M, Jhunjhunwala S, Kowanetz M, O'Gorman WE, Hegde PS, Sumatoh H, Lee BH, Nardin A, Becht E, Flynn S, Ballinger M, Newell EW, Yadav M.

J Immunother Cancer. 2019 Sep 12;7(1):249. doi: 10.1186/s40425-019-0695-9.

2.

Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.

Snyder A, Nathanson T, Funt SA, Ahuja A, Buros Novik J, Hellmann MD, Chang E, Aksoy BA, Al-Ahmadie H, Yusko E, Vignali M, Benzeno S, Boyd M, Moran M, Iyer G, Robins HS, Mardis ER, Merghoub T, Hammerbacher J, Rosenberg JE, Bajorin DF.

PLoS Med. 2017 May 26;14(5):e1002309. doi: 10.1371/journal.pmed.1002309. eCollection 2017 May.

3.

Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.

Tan LC, Mowat AG, Fazou C, Rostron T, Roskell H, Dunbar PR, Tournay C, Romagné F, Peyrat MA, Houssaint E, Bonneville M, Rickinson AB, McMichael AJ, Callan MF.

Arthritis Res. 2000;2(2):154-64. Epub 2000 Feb 7.

4.

Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells.

Fehlings M, Simoni Y, Penny HL, Becht E, Loh CY, Gubin MM, Ward JP, Wong SC, Schreiber RD, Newell EW.

Nat Commun. 2017 Sep 15;8(1):562. doi: 10.1038/s41467-017-00627-z. Erratum in: Nat Commun. 2018 Jul 26;9(1):3000.

5.

Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.

Wu SP, Liao RQ, Tu HY, Wang WJ, Dong ZY, Huang SM, Guo WB, Gou LY, Sun HW, Zhang Q, Xie Z, Yan LX, Su J, Yang JJ, Zhong WZ, Zhang XC, Wu YL.

J Thorac Oncol. 2018 Apr;13(4):521-532. doi: 10.1016/j.jtho.2017.11.132. Epub 2017 Dec 18.

6.

Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.

Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM, Trebska-McGowan K, Wunderlich JR, Yang JC, Rosenberg SA.

Nat Med. 2016 Apr;22(4):433-8. doi: 10.1038/nm.4051. Epub 2016 Feb 22.

PMID:
26901407
7.

A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8+ T-cell Responses, Impacting Tumor Challenge.

Duperret EK, Perales-Puchalt A, Stoltz R, G H H, Mandloi N, Barlow J, Chaudhuri A, Sardesai NY, Weiner DB.

Cancer Immunol Res. 2019 Feb;7(2):174-182. doi: 10.1158/2326-6066.CIR-18-0283. Epub 2019 Jan 24.

PMID:
30679156
8.

Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.

Martin SD, Brown SD, Wick DA, Nielsen JS, Kroeger DR, Twumasi-Boateng K, Holt RA, Nelson BH.

PLoS One. 2016 May 18;11(5):e0155189. doi: 10.1371/journal.pone.0155189. eCollection 2016.

9.

Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates.

Simoni Y, Becht E, Fehlings M, Loh CY, Koo SL, Teng KWW, Yeong JPS, Nahar R, Zhang T, Kared H, Duan K, Ang N, Poidinger M, Lee YY, Larbi A, Khng AJ, Tan E, Fu C, Mathew R, Teo M, Lim WT, Toh CK, Ong BH, Koh T, Hillmer AM, Takano A, Lim TKH, Tan EH, Zhai W, Tan DSW, Tan IB, Newell EW.

Nature. 2018 May;557(7706):575-579. doi: 10.1038/s41586-018-0130-2. Epub 2018 May 16.

PMID:
29769722
10.

Persistent viral infection in humans can drive high frequency low-affinity T-cell expansions.

Khan N, Cobbold M, Cummerson J, Moss PA.

Immunology. 2010 Dec;131(4):537-48. doi: 10.1111/j.1365-2567.2010.03326.x. Epub 2010 Aug 16.

11.

Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer.

O'Donnell T, Christie EL, Ahuja A, Buros J, Aksoy BA, Bowtell DDL, Snyder A, Hammerbacher J.

BMC Cancer. 2018 Jan 22;18(1):87. doi: 10.1186/s12885-017-3825-0.

12.

Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood.

Peng S, Zaretsky JM, Ng AHC, Chour W, Bethune MT, Choi J, Hsu A, Holman E, Ding X, Guo K, Kim J, Xu AM, Heath JE, Noh WJ, Zhou J, Su Y, Lu Y, McLaughlin J, Cheng D, Witte ON, Baltimore D, Ribas A, Heath JR.

Cell Rep. 2019 Sep 3;28(10):2728-2738.e7. doi: 10.1016/j.celrep.2019.07.106.

13.

Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes.

Gros A, Tran E, Parkhurst MR, Ilyas S, Pasetto A, Groh EM, Robbins PF, Yossef R, Garcia-Garijo A, Fajardo CA, Prickett TD, Jia L, Gartner JJ, Ray S, Ngo L, Wunderllich JR, Yang JC, Rosenberg SA.

J Clin Invest. 2019 Oct 14. pii: 127967. doi: 10.1172/JCI127967. [Epub ahead of print]

PMID:
31609250
14.

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, Yi J, Sandler A, Rittmeyer A; POPLAR Study Group.

Lancet. 2016 Apr 30;387(10030):1837-46. doi: 10.1016/S0140-6736(16)00587-0. Epub 2016 Mar 10.

PMID:
26970723
15.

Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer.

Liu S, Matsuzaki J, Wei L, Tsuji T, Battaglia S, Hu Q, Cortes E, Wong L, Yan L, Long M, Miliotto A, Bateman NW, Lele SB, Chodon T, Koya RC, Yao S, Zhu Q, Conrads TP, Wang J, Maxwell GL, Lugade AA, Odunsi K.

J Immunother Cancer. 2019 Jun 20;7(1):156. doi: 10.1186/s40425-019-0629-6.

16.

Expansion of peripheral CD8+ CD28- T cells in response to Epstein-Barr virus in patients with rheumatoid arthritis.

Klatt T, Ouyang Q, Flad T, Koetter I, Bühring HJ, Kalbacher H, Pawelec G, Müller CA.

J Rheumatol. 2005 Feb;32(2):239-51.

PMID:
15693083
17.

Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.

Tischer S, Dieks D, Sukdolak C, Bunse C, Figueiredo C, Immenschuh S, Borchers S, Stripecke R, Maecker-Kolhoff B, Blasczyk R, Eiz-Vesper B.

J Immunol Methods. 2014 Jun;408:101-13. doi: 10.1016/j.jim.2014.05.011. Epub 2014 May 28.

PMID:
24877879
18.

Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing.

Karasaki T, Nagayama K, Kuwano H, Nitadori JI, Sato M, Anraku M, Hosoi A, Matsushita H, Takazawa M, Ohara O, Nakajima J, Kakimi K.

Cancer Sci. 2017 Feb;108(2):170-177. doi: 10.1111/cas.13131. Epub 2017 Feb 9.

19.

[MHC tetramers: tracking specific immunity].

Kosor E, Gagro A, Drazenović V, Kuzman I, Jeren T, Rakusić S, Rabatić S, Markotić A, Gotovac K, Sabioncello A, Cecuk E, Kerhin-Brkljacić V, Gjenero-Margan I, Kaić B, Mlinarić-Galinović G, Kastelan A, Dekaris D.

Acta Med Croatica. 2003;57(4):255-9. Review. Croatian.

PMID:
14639858
20.

Identification of a neoantigen epitope in a melanoma patient with good response to anti-PD-1 antibody therapy.

Nonomura C, Otsuka M, Kondou R, Iizuka A, Miyata H, Ashizawa T, Sakura N, Yoshikawa S, Kiyohara Y, Ohshima K, Urakami K, Nagashima T, Ohnami S, Kusuhara M, Mitsuya K, Hayashi N, Nakasu Y, Mochizuki T, Yamaguchi K, Akiyama Y.

Immunol Lett. 2019 Apr;208:52-59. doi: 10.1016/j.imlet.2019.02.004. Epub 2019 Mar 14.

Supplemental Content

Support Center